Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Voyageur Pharmaceuticals ( (TSE:VM) ) just unveiled an update.
Voyageur Pharmaceuticals has initiated its first commercial shipments of Health Canada-approved barium contrast products to Canadian clinics, marking a significant milestone in its operations. This development is expected to aid in the company’s global expansion efforts and enhance its strategic positioning by leveraging its Frances Creek Project, which offers low-cost production and long-term supply advantages, supporting North American supply chain independence and sustainability goals.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals is a radiology contrast media company focused on vertical integration and supply chain security. The company specializes in barium contrast products for gastrointestinal imaging applications and is working towards expanding its distribution across Canada and potentially into the US market.
Average Trading Volume: 208,569
Technical Sentiment Signal: Buy
Current Market Cap: C$26.08M
For detailed information about VM stock, go to TipRanks’ Stock Analysis page.